Retatrutide, a experimental dual agonist of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) binding site , is demonstrating promising outcomes in initial human assessments . https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/